AKBAAkebia Therapeutics

$8.75
$-0.25 (-3%)

Akebia Therapeutics (AKBA) Stock Analysis

Create a FREE Account to View Full AKBA Stock Report

Akebia Therapeutics (AKBA) Analyst Forecast

Next 12 months ➝Current Price$8.7552-week High$9.4052-week Low$2.99MEAN$12.33+40.95%HIGH$16.00+82.86%LOW$9.00+2.86%
  • Last Price$8.75
  • Previous Close$9.00
  • Change $-0.25
  • Open$9.01
  • Volume1,082,441
  • Avg. Volume (100-day)1,268,750
  • Market Capitalization$1.04B
  • Days Range $8.64 - $9.10
  • 52-week Range $2.99 - $9.40
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-2.5
  • Earnings Date03/24/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta2.418
  • PEG Ratio
  • Volatility0.85
  • Average True Range0.07
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.